Open Access Open Access  Restricted Access Subscription Access

An Important Parameters of Quinolones

Muralinath E., Mr. Vonteru Munisekhar, Dr. P. Prabhavathi., K. Suparnalatha., M. Harshita., Dr. G. Rajeswari., Sravani Pragna. K., Guruprasad M.

Abstract


A class of broad-spectrum antibiotics called quinolones is used to treat and manage a wide range of bacterial illnesses. In order to help healthcare team members manage the care of patients with bacterial infections treated with quinolones and their possible side effects, this activity explains the indications, contraindications, mechanism of action, adverse events, and other important aspects of quinolone therapy in the clinical setting.


Full Text:

PDF

References


Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014). Mechanism of quinolone action and resistance. Biochemistry, 53(10), 1565–1574.

Bisacchi, G. S., & Hale, M. R. (2016). A “double-edged” scaffold: Antitumor power within the antibacterial quinolone. Current Medicinal Chemistry, 23(6), 520–577.

BT, Steele, J. M., Thomas, S. J., Bohan, K. H., & Kufel, W. D. (2018). Clinical review of delafloxacin: A novel anionic fluoroquinolone. Journal of Antimicrobial Chemotherapy, 73(6), 1439–1451.

Chien, S. C., Rogge, M. C., Gisclon, L. G., Curtin, C., Wong, F., Natarajan, J., Williams, R. R., Fowler, C. L., Cheung, W. K., & Chow, A. T. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy, 41(10), 2256–2260.

Dagrosa, E. E., Verho, M., Malerczyk, V., de Looze, S., Hajdú, P., & Toyodera, K. (1986). Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent. Clinical Therapeutics, 8(6), 632–645.

Fedorowicz, J., & Sączewski, J. (2018). Modifications of quinolones and fluoroquinolones: Hybrid compounds and dual-action molecules. Monatshefte für Chemie—Chemical Monthly, 149(7), 1199–1245.

Fish, D. N., & Chow, A. T. (1997). The clinical pharmacokinetics of levofloxacin. Clinical Pharmacokinetics, 32(2), 101–119.

Flor, S. (1989). Pharmacokinetics of ofloxacin: An overview. The American Journal of Medicine, 87(6C), 24S–30S.

Guay, D., Tack, K., & Flor, S. (1991). Safety and pharmacokinetics of single dose intravenous ofloxacin in healthy volunteers. International Journal of Clinical Pharmacology Research, 11(5), 203–209.

Horcajada, J. P., Salata, R. A., Álvarez-Sala, R., Nitu, F. M., Lawrence, L., Quintas, M., Cheng, C. Y., Cammarata, S., & DEFINE-CABP Study Group. (2020). A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infectious Diseases, 7(1), Article ofz514.

Jackson, M. A., & Schutze, G. E. (2016). The use of systemic and topical fluoroquinolones. Pediatrics, 138(5).

Lode, H., Höffken, G., Boeckk, M., Deppermann, N., Borner, K., & Koeppe, P. (1990). Quinolone pharmacokinetics and metabolism. Journal of Antimicrobial Chemotherapy, 26(Suppl. B), 41–49.

Mant, T. G. (1992). Multiple-dose pharmacokinetics of lomefloxacin: Rationale for once-a-day dosing. The American Journal of Medicine, 92(4A), 26S–32S.

Naidoo, A., Naidoo, K., McIlleron, H., Essack, S., & Padayatchi, N. (2017). A review of moxifloxacin for the treatment of drug-susceptible tuberculosis. The Journal of Clinical Pharmacology, 57(11), 1369–1386.

Naeem, A., Badshah, S. L., Muska, M., Ahmad, N., & Khan, K. (2016). The current case of quinolones: Synthetic approaches and antibacterial activity. Molecules, 21(4), Article 268.

Patel, K., & Goldman, J. L. (2016). Safety concerns surrounding quinolone use in children. The Journal of Clinical Pharmacology, 56(9), 1060–1075.

Pranger, A. D., van der Werf, T. S., Kosterink, J. G. W., & Alffenaar, J. W. C. (2019). The role of fluoroquinolones in the treatment of tuberculosis in 2019. Drugs, 79(2), 161–171.

Tyson, G. H., Li, C., Hsu, C. H., Bodeis-Jones, S., & McDermott, P. F. (2019). Diverse fluoroquinolone resistance plasmids from retail meat E. coli in the United States. Frontiers in Microbiology, 10, Article 2826.

Yadav, V., & Talwar, P. (2019). Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomedicine & Pharmacotherapy, 111, 934–946.

Yefet, E., Schwartz, N., Chazan, B., Salim, R., Romano, S., & Nachum, Z. (2018). The safety of quinolones and fluoroquinolones in pregnancy: A meta-analysis. BJOG: An International Journal of Obstetrics & Gynaecology, 125(9), 1069–1076.


Refbacks

  • There are currently no refbacks.